Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Financing Activities: 2017-2024

Historic Cash from Financing Activities for Solid Biosciences (SLDB) over the last 5 years, with Dec 2024 value amounting to $6.9 million.

  • Solid Biosciences' Cash from Financing Activities rose 1274.26% to $6.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $122.4 million, marking a year-over-year increase of 62.57%. This contributed to the annual value of $122.4 million for FY2024, which is 3821.75% up from last year.
  • Latest data reveals that Solid Biosciences reported Cash from Financing Activities of $6.9 million as of Q4 2024, which was up 113.14% from $3.3 million recorded in Q3 2024.
  • In the past 5 years, Solid Biosciences' Cash from Financing Activities ranged from a high of $135.2 million in Q1 2021 and a low of -$238,000 during Q2 2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $3.3 million (2024), whereas its average is $22.0 million.
  • The largest annual percentage gain for Solid Biosciences' Cash from Financing Activities in the last 5 years was 113,137.88% (2022), contrasted with its biggest fall of 133.33% (2022).
  • Solid Biosciences' Cash from Financing Activities (Quarterly) stood at $66,000 in 2021, then spiked by 113,137.88% to $74.7 million in 2022, then plummeted by 99.32% to $505,000 in 2023, then soared by 1,274.26% to $6.9 million in 2024.
  • Its last three reported values are $6.9 million in Q4 2024, $3.3 million for Q3 2024, and $5.0 million during Q2 2024.